Article
Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
Journal of gastroenterology - 1 Oct 2017
Suda Goki, Ogawa Koji, Yamamoto Yoshiya, Katagiri Masaki, Furuya Ken, Kumagai Kenichi, Konno Jun, Kimura Megumi, Kawagishi Naoki, Ohara Masatsugu, Umemura Machiko, Ito Jun, Izumi Takaaki, Nakai Masato, Sho Takuya, Natsuizaka Mitsuteru, Morikawa Kenichi, Tsubota Akihito, Shimada Noritomo, Iio Etsuko, Tanaka Yasuhito, Sakamoto Naoya
Abstract excerpt
BACKGROUND: The optimal retreatment regimen for patients with hepatitis C virus (HCV) infection who failed interferon-free, direct-acting antiviral (DAA) therapy is undetermined. In this study, we aimed to evaluate the efficacy and safety of 12-week retreatment with ledipasvir (LDV) and sofosbuvir (SOF) with add-on ribavirin (RBV) for patients who previously failed to respond to HCV-NS5A inhibitor, daclatasvir...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.